Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Orphanet Journal of Rare Diseases
Published in: Orphanet Journal of Rare Diseases 1/2017

Open Access 01-12-2017 | Research

The burden of amyloid light chain amyloidosis on health-related quality of life

Authors: Martha Bayliss, Kristen L. McCausland, Spencer D. Guthrie, Michelle K. White

Published in: Orphanet Journal of Rare Diseases | Issue 1/2017

Login to get access

Abstract

Background

Light chain (AL) amyloidosis is a rare disease characterized by misfolded amyloid protein deposits in tissues and vital organs, and little is known about the burden of AL amyloidosis on health-related quality of life. This study aimed to quantify the burden of AL amyloidosis in terms of health-related quality of life in a diverse, community-based sample of AL amyloidosis patients.

Results

The SF-36v2® Health Survey (SF-36v2), a widely used generic measure of health-related quality of life (using physical and mental summary scales and subscales assessing eight aspects of functioning and well-being), was administered as an online survey of AL amyloidosis patients with AL amyloidosis (ClinicalTrials.gov, NCT02574676; n = 341). Compared with adjusted general population sample norms, health-related quality of life of AL amyloidosis patients was significantly worse across all SF-36v2 scales and summary measures based on analysis of variance (p < 0.05 for all). The largest decrement in AL amyloidosis patients was related to General Health (Δ = 9.7; p < 0.001). With the exception of Bodily Pain and Mental Health, differences were also clinically meaningful based on established clinically minimal important differences. The burden of AL amyloidosis overall and in key subgroups tended to be greater on physical health than on mental health. Stratified analyses indicated additional burden among patients with recently diagnosed disease and those with cardiac involvement than among their respective counterparts.

Conclusion

Understanding the burden of AL amyloidosis highlights the unmet need for treatment, helps physicians identify ancillary treatments and services geared towards improving patients’ functioning, well-being, and overall health-related quality of life. These findings also help to support the use of health-related quality of life end points as important outcome measures in current and future treatment studies.

Trial registration

ClinicalTrials.gov, NCT02574676. Registered October 5, 2015.
Literature
1.
Gertz MA. Immunoglobulin light chain amyloidosis: 2013 update on diagnosis, prognosis, and treatment. Am J Hematol. 2013;88:416–25.CrossRefPubMed
2.
3.
Kyle RA, Linos A, Beard CM, Linke RP, Gertz MA, O’Fallon WM, et al. Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989. Blood. 1992;79:1817–22.PubMed
4.
Pinney JH, Smith CJ, Taube JB, Lachmann HJ, Venner CP, Gibbs SD, et al. Systemic amyloidosis in England: an epidemiological study. Br J Haematol. 2013;161:525–32.CrossRefPubMedPubMedCentral
5.
Muchtar E, Buadi FK, Dispenzieri A, Gertz MA. Immunoglobulin light-chain amyloidosis: from basics to new developments in diagnosis, prognosis and therapy. Acta Haematol. 2016;135:172–90.CrossRefPubMed
6.
7.
8.
Cohen AD, Zhou P, Chou J, Teruya-Feldstein J, Reich L, Hassoun H, et al. Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/− thalidomide for systemic light-chain amyloidosis: results of a phase II trial. Br J Haematol. 2007;139:224–33.CrossRefPubMed
9.
Sanchorawala V, Skinner M, Quillen K, Finn KT, Doros G, Seldin DC. Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation. Blood. 2007;110:3561–3.CrossRefPubMedPubMedCentral
10.
Lin HM, Seldin D, Hui A, Berg D, Dietrich CN, Flood E. The patient’s perspective on the symptom and everyday life impact of AL amyloidosis. Amyloid. 2015;22:244–51.CrossRefPubMed
11.
White MK, Bayliss M, Finkel M, Lousada I, Guthrie S. Health-related quality of life in patients with AL amyloidosis: qualitative interviews with physicians and patients. Presented at: American Society of Hematology 57th Annual Meeting and Exposition; December 5–8, 2015. Orlando: Abstract; 2015.
12.
Smorti M, Guarnieri S, Bergesio F, Perfetto F, Cappelli F. Anxiety and depression among amyloid light-chain cardiac amyloidosis patients: the role of life satisfaction. Eur J Cardiovasc Nurs. 2016;15:269–75.CrossRefPubMed
13.
Caccialanza R, Palladini G, Klersy C, Cereda E, Bonardi C, Cameletti B, et al. Nutritional status independently affects quality of life of patients with systemic immunoglobulin light-chain (AL) amyloidosis. Ann Hematol. 2012;913:399–406.CrossRef
14.
Seldin DC, Anderson JJ, Sanchorawala V, Malek K, Wright DG, Quillen K, et al. Improvement in quality of life of patients with AL amyloidosis treated with high-dose melphalan and autologous stem cell transplantation. Blood. 2004;104:1888–93.CrossRefPubMed
15.
Maruish ME. User’s Manual for the SF-36v2 Health Survey. 3rd ed. Lincoln: QualityMetric, Inc.; 2011.
16.
Lee CW, Chi KN. The standard of reporting of health-related quality of life in clinical cancer trials. J Clin Epidemiol. 2000;53:451–8.CrossRefPubMed
17.
18.
Ware Jr JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36), I: conceptual framework and item selection. Med Care. 1992;30:473–83.CrossRefPubMed
19.
Hendriksz CJ, Berger KI, Lampe C, Kircher SG, Orchard PJ, Southall R, et al. Health-related quality of life in mucopolysaccharidosis: looking beyond biomedical issues. Orphanet J Rare Dis. 2016;11:119.CrossRefPubMedPubMedCentral
20.
Bosch AM, Burlina A, Cunningham A, Bettiol E, Moreau-Stucker F, Koledova E, et al. Assessment of the impact of phenylketonuria and its treatment on quality of life of patients and parents from seven European countries. Orphanet J Rare Dis. 2015;10:80.CrossRefPubMedPubMedCentral
21.
Palladini G, Dispenzieri A, Gertz MA, Kumar S, Wechalekar A, Hawkins PN, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Onco. 2012;30:4541–9.CrossRef
22.
Guy W. ECDEU Assessment Manual for Psychopharmacology. Rockville: U.S. Department of Health Education and Welfare Public Health Service Alcohol Drug Abuse and Mental Health Administration National Institute of Mental Health Psychopharmacology Research Branch; 1976.
23.
24.
Cox S, O’Donoghue AC, McKenna WJ, Steptoe A. Health related quality of life and psychological wellbeing in patients with hypertrophic cardiomyopathy. Heart. 1997;78:182–7.CrossRefPubMedPubMedCentral
25.
Merlini G, Wechalekar AD, Palladini G. Systemic light chain amyloidosis: an update for treating physicians. Blood. 2013;121:5124–30.CrossRefPubMed
26.
Kumar SK, Gertz MA, Lacy MQ, Dingli D, Hayman SR, Buadi FK, et al. Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score. Mayo Clin Proc. 2011;86:12–8.CrossRefPubMedPubMedCentral
27.
Grogan M, Dispenzieri A. Natural history and therapy of AL cardiac amyloidosis. Heart Fail Rev. 2015;20:155–62.CrossRefPubMed
28.
Szklo M, Nieto FJ. Epidemiology: Beyond the Basics. Gaithersburg: Aspen Publishers; 2000.
29.
Merlini G. Plasma cell disorder other than myeloma: treatment of amyloidosis. Presented at: American Society of Hematology 57th Annual Meeting and Exposition; December 5–8, 2015. Orlando: Education Spotlight Session; 2015.
30.
Metadata
Title
The burden of amyloid light chain amyloidosis on health-related quality of life
Authors
Martha Bayliss
Kristen L. McCausland
Spencer D. Guthrie
Michelle K. White
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Orphanet Journal of Rare Diseases / Issue 1/2017
Electronic ISSN: 1750-1172
DOI
https://doi.org/10.1186/s13023-016-0564-2

Other articles of this Issue 1/2017

Orphanet Journal of Rare Diseases 1/2017 Go to the issue

Research

Down-regulation of miR-9* in the peripheral leukocytes of Huntington’s disease patients

Research

Identification of EML4-ALK as an alternative fusion gene in epithelioid inflammatory myofibroblastic sarcoma

Research

Clinical, biochemical and molecular characterization of Korean patients with mucolipidosis II/III and successful prenatal diagnosis

Research

Determinants of impaired quality of life in patients with fibrous dysplasia

Review

Review of 11 national policies for rare diseases in the context of key patient needs

Research

Moebius sequence –a multidisciplinary clinical approach